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Arteriovenous ﬁstula patency in the 3 years following
vonapanitase and placebo treatment
Eric K. Peden, MD,a Timothy P. O’Connor, MD,b Barry J. Browne, MD,c Bradley S. Dixon, MD,d
Andres S. Schanzer, MD,e Stephen C. Jensik, MD,f Albert D. Sam II, MD,g and Steven K. Burke, MD,h
Houston, Tex; Peoria and Chicago, Ill; San Diego, Calif; Iowa City, Iowa; Worcester andWaltham, Mass; and NewOrleans, La
ABSTRACT
Objective: This study explored the long-term outcomes of arteriovenous ﬁstulas treated with vonapanitase (recombinant
human elastase) at the time of surgical creation.
Methods: This was a randomized, double-blind, placebo-controlled trial of 151 patients undergoing radiocephalic or
brachiocephalic arteriovenous ﬁstula creation who were randomized equally to placebo, vonapanitase 10 mg, or
vonapanitase 30 mg. The results after 1 year of follow-up were previously reported. The current analysis occurred when the
last patient treated was observed for 3 years. For the current analysis, the primary end point was primary patency; the
secondary end points included secondary patency, use of the ﬁstula for hemodialysis, and rate of procedures to restore or
to maintain patency.
Results: There was no signiﬁcant difference in the risk of primary patency loss with vonapanitase 10 mg or 30 mg vs
placebo. When seven initial patency loss events related to cephalic arch and central vein balloon angioplasty were
excluded, the risk of patency loss was reduced with vonapanitase overall (hazard ratio [HR], 0.63; P ¼ .049) and 30 mg
(HR, 0.51; P ¼ .03). In patients with radiocephalic ﬁstulas (n ¼ 67), the risks of primary and secondary patency loss were
reduced with 30 mg (HR, 0.37 [P ¼ .02] and 0.24 [P ¼ .046], respectively). The rate of procedures to restore or to maintain
ﬁstula patency was reduced with 30 mg vs placebo (0.23 vs 0.72 procedure days/patient/year; P ¼ .03) and also reduced in
patients with radiocephalic ﬁstulas with 30 mg vs placebo (0.17 vs 0.85 procedure days/patient/year; P ¼ .048).
Conclusions: In this study, vonapanitase did not signiﬁcantly improve primary patency in the primary analysis but did
signiﬁcantly improve primary patency in an analysis that excluded patency loss due to cephalic arch and central vein
balloon angioplasty. In patients with radiocephalic ﬁstulas, 30 mg signiﬁcantly improved primary and secondary patency.
Vonapanitase 30 mg decreased the rate of procedures to restore or to maintain patency in the analysis that included all
patients and in the subset with radiocephalic ﬁstulas. (J Vasc Surg 2017;65:1113-20.)
A functional arteriovenous ﬁstula (AVF) is the preferred
form of hemodialysis vascular access because of supe-
rior patency and reduced need for corrective proced-
ures compared with other forms of access.1,2 However,
AVFs often fail to mature and frequently experience
loss of primary unassisted patency (primary patency).1,3,4
Patency loss is typically the result of stenosis formation
due to neointimal hyperplasia and is manifested as
AVF thrombosis or diminished AVF blood ﬂow, resulting
in inadequate hemodialysis and the need for interven-
tional or surgical procedures.1 Many AVFs also experi-
ence loss of secondary patency, deﬁned as AVF
abandonment.3,4
Vonapanitase (formerly PRT-201) is a recombinant
human chymotrypsin-like elastase family member 1
(CELA1).5 Vonapanitase is applied topically to the external
adventitial surface of the surgically exposed inﬂow artery,
anastomosis, and outﬂow vein immediately after AVF
creation with the intent of improving AVF maturation
and patency. Vonapanitase locally fragments the protein
elastin in elastic ﬁbers present in the blood vessel walls,
liberating peptide fragments that may be chemoattrac-
tants for the cells that participate in the formation of
intimal hyperplasia.6-8
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A previous clinical trial suggested that vonapanitase at
doses of 0.0033 to 0.033 mg may decrease hemodynam-
ically signiﬁcant AVF lumen stenosis, decrease the need
for balloon angioplasty, and prolong AVF primary
patency.9 On the basis of these promising ﬁndings, two
vonapanitase doses, 0.01 mg and 0.03 mg (10 mg and
30 mg), were selected for investigation in the current
randomized, double-blind placebo-controlled trial in
patients undergoing placement of a radiocephalic or
brachiocephalic AVF. The primary efﬁcacy analysis at
1 year was previously published.10 In that analysis, vona-
panitase 30 mg was associated with a signiﬁcant
improvement in unassisted maturation at 3 months by
duplex Doppler ultrasound imaging. Vonapanitase
30 mg was also associated with a nonsigniﬁcant 33%
decrease in the risk of primary patency loss and a signif-
icant 63% decrease in the risk of primary patency loss in
patients with radiocephalic AVFs. Patients completing
the 12 months of follow-up entered a registry to track
long-term outcomes. Here we present the results of an
efﬁcacy analysis after an additional 2 years of follow-up.
The aim was to describe the long-term effects of vonapa-
nitase treatment on clinically relevant end points such as
patency and use of the AVF for hemodialysis.
METHODS
This studywas aprospective, observational follow-upof a
randomized, double-blind, placebo-controlled trial. A full
list of participating centers and the number of patients
treated at each can be found in the Acknowledgments.
The protocol, informed consent form, and all amend-
mentswere reviewed andapprovedby each center’s Insti-
tutional Review Board. This study was conducted in
accordance with the ethical principles originating from
the Declaration of Helsinki and current Good Clinical
Practices and in compliance with the Code of Federal
Regulations (21 CFR 312). All patients who participated
signed an informed consent document. The trial was
preregistered at www.clinicaltrials.gov and enrolled pa-
tientswith chronic kidneydiseasewhowere onhemodial-
ysis or planning to initiate hemodialysis within 6 months
and were undergoing creation of a radiocephalic or bra-
chiocephalic AVF. Exclusion criteria were age <18 years,
life expectancy <6 months, pregnancy, history of arterial
aneurysm, previous treatment with vonapanitase, malig-
nant disease, and signiﬁcant liver disease. Selection of
the AVF locationwas left to the surgeon. Because radioce-
phalic and brachiocephalic AVFs were allowed, it was
assumed the surgeon would choose the best access for
each patient based on the patient’s characteristics
including the results of veinmapping,whichwas standard
of care.
Patients were randomized equally into one of three
dose groupsdplacebo, 10 mg, or 30 mgeusing block
sizes of six. Vonapanitase was provided as a lyophilized
powder in 5-mg vials that were reconstituted with
phosphate-buffered saline containing 0.01% polysorbate
80 and diluted to ﬁnal concentrations of 4 or 12 mg/mL
by an unblinded research pharmacist. The placebo was
the reconstitution ﬂuid and was identical in appearance
to the vonapanitase solution. Immediately after creation
of the AVF, a 2.5-mL solution was topically applied as a
series of drops during 10 minutes to the exposed inﬂow
artery, anastomosis, and outﬂow vein including the
mobilized vein swing segment, after which the area
was lavaged for 1 minute with saline solution. After
surgery and drug administration, in-person visits
occurred at weeks 2 and 6 and months 3, 6, 9, and 12.
Thereafter, patients were contacted every 3 months
either by in-person visits or by a phone call to the patient,
the patient’s family, or caregivers. The treatment assign-
ment remained double-blinded until the month 12 visit,
after which the study sponsor (Proteon Therapeutics)
was unblinded. The trial teams and patients remained
blinded to treatment assignment throughout the entire
follow-up period. Follow-up ended at the time of the
analysis for patients still active in the study, when a
patient’s AVF was abandoned, or at the last study visit
for patients who terminated early (died, received a
kidney transplant, switched to peritoneal dialysis, with-
drew consent, or were lost to follow-up). Data collected




10 mg (n ¼ 51)
Vonapanitase
30 mg (n ¼ 49)
Male 32 (63) 28 (55) 27 (55)
White 32 (63) 40 (78) 36 (74)
Age, years 59 6 15 59 6 18 59 6 15
$65 years 18 (35) 23 (45) 15 (31)
BMI,a kg/m2 31 6 8 31 6 8 35 6 8
RC AVF 24 (47) 23 (45) 20 (41)
IHD 25 (49) 30 (59) 28 (57)
PAD 15 (29) 10 (20) 11 (22)
CVD 9 (18) 11 (22) 11 (22)
On hemodialysis 22 (43) 23 (45) 14 (29)
Central venous
catheter
22 (43) 21 (41) 16 (33)
Ipsilateral central
venous catheter
5 (10) 4 (8) 4 (8)
CKD secondary
to DM
20 (39) 22 (43) 27 (55)
CKD secondary
to HTN
18 (35) 14 (27) 11 (22)
Duration of
CKD, months
44 6 44 54 6 66 60 6 75
AVF, Arteriovenous ﬁstula; BMI, body mass index; CKD, chronic kidney
disease; CVD, cerebrovascular disease; DM, diabetes mellitus; HTN,
hypertension; IHD, ischemic heart disease; PAD, peripheral artery dis-
ease; RC, radiocephalic.
Categorical variables are presented as number (%). Continuous vari-
ables are presented as mean 6 standard deviation.
aUnpaired t-test, P < .01.
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included adverse events (all events until week 6, then
events related to the arm with the AVF until month 12);
physical examinations (general examination before sur-
gery and at week 6 and AVF arm examination at all visits
to month 12); duplex Doppler ultrasound examinations
(week 6 and month 3); and safety laboratory determina-
tions, including a chemistry panel, complete blood cell
count, and antivonapanitase antibodies (before surgery
and at week 6). In addition, the date of hemodialysis
initiation, AVF use for hemodialysis, reasons for nonuse,
reasons for AVF abandonment, complications associated
with the AVF, and procedures performed on the AVF
were collected for the entire follow-up period. A
previous publication reported the results of analyses
conducted through month 12.10 The current analysis
was completed after the last patient treated was
observed for a total of 3 years. The primary efﬁcacy end
point was primary patency, deﬁned as the time from
AVF creation until ﬁrst occurrence of either AVF throm-
bosis detected by physical examination or imaging or
an invasive procedure to restore or to maintain AVF
patency including thrombectomy, thrombolysis, balloon
angioplasty, stent placement, and surgical revision. Pro-
cedure reports were reviewed to conﬁrm accurate
reporting.
Secondary efﬁcacy end points included secondary
patency (time from AVF creation to abandonment),
procedure rate (total number of days on which invasive
procedures were performed to the AVF, divided by
post-treatment follow-up time), and AVF use for hemodi-
alysis. AVF use for hemodialysis was deﬁned as use of the
trial AVF for hemodialysis for $3 months. If hemodialysis
was not initiated at least 3 months before the end of the
study, successful use was deﬁned as use for at least
1 month and in use at the patient’s last study visit.
Nonuse was deﬁned as AVF abandonment before can-
nulation or hemodialysis for two consecutive trial visits
($3 months apart) without use of the trial AVF. Unas-
sisted use was deﬁned as AVF use for hemodialysis
without any prior procedures performed to restore or to
maintain AVF patency. Assisted use was deﬁned as AVF
use for hemodialysis with at least one prior procedure
performed to restore or to maintain AVF patency. Any
use was the sum of unassisted and assisted use.
For powering, it was assumed that 50% of placebo
patients, 80% of patients receiving 10 mg, and 80% of
patients receiving 30 mg would retain AVF primary
patency, equating to a hazard ratio (HR) of 0.32 (ie, a
68% reduction in risk of primary patency loss). Group
sizes of 50 provided 80% power using a two-sided
Consented (n=198) 
Randomized (n=169) 
 Placebo (n=57) 
  Did not receive (n=6) 
  Received treatment (n=51) 
 Completed (n=19) 
 AVF abandoned (n=15) 
 Terminated early (n=17) 
   Died (n=8) 
   Transplant (n=6) 
   Switch to PD (n=0) 
   Lost to FU (n=3) 
  Analyzed (n=51) 
 Vonapanitase 10 µg (n=59) 
  Did not receive (n=8) 
  Received treatment (n=51) 
 Completed (n=19) 
 AVF abandoned (n=12) 
 Terminated early (n=20) 
   Died (n=7) 
   Transplant (n=4) 
   Switch to PD (n=1) 
   Lost to FU (n=8) 
  Analyzed (n=51) 
 Vonapanitase 30 µg (n=53) 
  Did not receive (n=4) 
  Received treatment (n=49) 
 Completed (n=25) 
 AVF abandoned (n=10) 
 Terminated early (n=14) 
   Died (n=5) 
   Transplant (n=0) 
   Switch to PD (n=2) 
   Lost to FU (n=7) 
  Analyzed (n=49) 
Excluded (n=29) 
Fig 1. Flow of patients through the study. AVF, Arteriovenous ﬁstula; FU, follow-up; PD, peritoneal dialysis.
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log-rank test assuming a ¼ .05. Primary patency time was
estimated using Kaplan-Meier life test methods. Patients
without primary patency loss were censored at the date
of the last visit. The HR for each vonapanitase dose vs pla-
cebo was calculated using a Cox proportional hazards
model including treatment as the covariate. A sensitivity
analysis was conducted that excluded primary patency
loss events solely due to balloon angioplasty of cephalic
arch or central vein stenosis. In this sensitivity analysis,
the affected patients remained at risk for primary
patency loss due to subsequent AVF thrombosis or pro-
cedures to restore or to maintain patency in the arm
with the AVF.
Analyses similar to those described for primary patency
were performed for secondary patency (ie, Kaplan-Meier
life test methods, log-rank tests, and Cox proportional
hazards including treatment as the covariate). The
number of days on which patients had procedures was
summarized, and procedure days per patient per year
were calculated; the groups were compared with a
Wilcoxon rank sum test. The number and percentage
of patients with successful use of the AVF for hemodial-
ysis were summarized and tested using a c2 test. Patients
who never initiated dialysis were excluded. All analyses
were repeated for patients who underwent creation of
radiocephalic AVFs and separately for brachiocephalic
AVFs. All statistical analyses were performed using SAS
software, version 9.2 or higher (SAS Institute, Cary, NC).
RESULTS
There were 151 patients enrolled between April 2011 and
November 2012. Table I summarizes the patients’ base-
line characteristics. None of the differences between
groups were statistically signiﬁcant with the exception
of body mass index, which was highest in the 30-mg
group. The current analysis was performed when the
last patient treated was observed for 3 years, which
occurred in November 2015. At the time of analysis,
Fig 2. Arteriovenous ﬁstula (AVF) primary patency: red, vonapanitase 30 mg; green, vonapanitase 10 mg; black,
placebo. A, All AVFs. B, All AVFs excluding patency loss events due to angioplasty of cephalic arch or central
vein stenosis. C, Radiocephalic AVFs. D, Brachiocephalic AVFs.
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median post-treatment follow-ups were 633, 537, and
1079 days for placebo, 10 mg, and 30 mg, respectively.
Fewer patients in the 30-mg group had the AVF aban-
doned or terminated early compared with the placebo
and 10-mg groups, explaining the differences in median
follow-up times (Fig 1). Because of AVF abandonments
and early terminations, there were a small number of
subjects at risk during the later years of follow-up. As a
result, the Kaplan-Meier curves should be interpreted
with caution at these later time points, especially in the
subsets by AVF type.
Median primary patency time (the time at which >50%
of patients in a group lost patency) was more than three-
fold longer with vonapanitase than with placebo (746 vs
224 days, respectively; Fig 2, A). However, the risk of
primary patency loss was not signiﬁcantly reduced vs pla-
cebo for 10 mg (HR, 0.81; 95% conﬁdence interval [CI],
0.48-1.36; P ¼ .42) or 30 mg (HR, 0.63; 95% CI, 0.36-1.10;
P ¼ .10) or for vonapanitase overall (HR, 0.71; 95% CI,
0.45-1.13; P ¼ .14). In the analysis excluding balloon angio-
plasty procedures directed at cephalic arch and central
vein stenosis in seven patients with brachiocephalic
AVFs (Fig 2, B), the risk of primary patency loss was
signiﬁcantly reduced vs placebo for 30 mg (HR, 0.51;
95% CI, 0.28-0.93; P ¼ .03) and for vonapanitase overall
(HR, 0.63; 95% CI, 0.39-1.01; P ¼ .049) but not for vonapa-
nitase 10 mg.
Among patients with radiocephalic AVFs, median
primary patency time was 125 days and 967 days with
the placebo and 10-mg groups and >1181 days with the
30-mg and vonapanitase overall groups (Fig 2, C). In this
subgroup, the risk of primary patency loss was signiﬁ-
cantly reduced vs placebo for both 30 mg (HR, 0.37; 95%
CI, 0.15-0.91; P ¼ .02) and vonapanitase overall (HR, 0.51;
95% CI, 0.26-0.99; P ¼ .04). The risk of primary patency
loss was not signiﬁcantly reduced for 10 mg. In patients
with brachiocephalic AVFs, there were no signiﬁcant dif-
ferences in primary patency in the primary analysis or in
Fig 3. Arteriovenous ﬁstula (AVF) secondary patency: red, vonapanitase 30 mg; green, vonapanitase 10 mg; black,
placebo. A, All AVFs. B, Radiocephalic AVFs. C, Brachiocephalic AVFs.
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the analysis excluding balloon angioplasty procedures
directed at cephalic arch or central vein stenosis (Fig 2, D).
The median secondary patency time was not reached
in any dose group (Fig 3, A) as less than half of patients
had their AVF abandoned in any group. Overall, the risk
of secondary patency loss was not signiﬁcantly reduced
vs placebo for 10 mg (HR, 0.79; 95% CI, 0.37-1.68;
P ¼ .54), 30 mg (HR, 0.68; 95% CI, 0.30-1.50; P ¼ .33), or
vonapanitase overall (HR, 0.73; 95% CI, 0.38-1.40;
P ¼ .34). However, in patients with radiocephalic AVFs,
the risk of secondary patency loss was signiﬁcantly
reduced vs placebo for 30 mg (HR, 0.24; 95% CI,
0.05-1.10; P ¼ .046) and vonapanitase overall (HR, 0.38;
95% CI, 0.14-1.01; P ¼ .04); the risk of secondary patency
loss with 10 mg vs placebo was not signiﬁcant in this
subgroup (Fig 3, B). Findings among patients with
brachiocephalic AVFs were similar to those seen for
patients overall (Fig 3, C).
At least one procedure to restore or to maintain AVF
patency was performed for 47% (24/51), 48% (24/50), and
29% (14/48) of patients in the placebo, 10-mg, and 30-mg
groups, respectively. The procedure rate per patient per
year was signiﬁcantly reduced with 30 mg vs placebo
(0.23 vs 0.72; P ¼ .03) and also in patients with radioce-
phalic AVFs (0.17 vs 0.85; P¼ .048; Table II). Similar ﬁndings
were seen when balloon angioplasty procedures directed
at cephalic arch and central vein stenosis were excluded.
At the 10-mg dose and in patients with brachiocephalic
AVFs, no signiﬁcant differences vs placebo were seen.
No statistically signiﬁcant differences were seen with
regard to achievement of unassisted use or any
successful use of the AVF for hemodialysis (Table III).
Findings were similar in patients with radiocephalic
and brachiocephalic AVFs (Table III). In patients with
radiocephalic AVFs, there tended to be a higher
proportion with any use of the AVF for hemodialysis
with 30 mg vs placebo (80% vs 56%; P ¼ .14).
Safety results during the ﬁrst 12 months were previously
reported, and there were no statistically signiﬁcant differ-
ences in adverse events between treatment groups.7
During the registry (ie, after the month 12 visit), medical
events of interest related to the AVF (infection, aneurysm,
pseudoaneurysm, and thrombosis) were reported in six
placebo patients (19%) and ﬁve vonapanitase patients
(8%). Aneurysm was reported in three placebo patients
(9%) and no vonapanitase patients.
DISCUSSION
In this study, no signiﬁcant differences were seen
between active treatment and placebo with regard to
primary patency time. However, when patency loss
events due to cephalic arch and central vein balloon
angioplasty were excluded, there was a signiﬁcant differ-
ence in primary patency for vonapanitase overall and
30 mg vs placebo. Stenosis in the cephalic arch or central
veins is far removed from the treatment site and thus is
unlikely to be modiﬁed by local treatment of vonapani-
tase, which is inactivated by blood and thus acts only
at the site of application.11 Overall, vonapanitase-treated
patients had a lower rate of procedures to restore or to
maintain patency vs placebo, with a signiﬁcant differ-
ence between 30 mg and placebo, and the relative
Table II. Rate of procedures to restore or to maintain patency per patient per year on trial
Variablea Placebo (n ¼ 51)
Vonapanitase
10 mgb (n ¼ 50) P valuec
Vonapanitase
30 mgb (n ¼ 48) P valuec
All AVFs
No. 51 50 48
All AVFs 0.72 (1.11) 0.74 (1.45) .93 0.23 (0.49) .03
All AVFs, excluding cephalic arch
and central vein procedures
0.71 (1.10) 0.70 (1.45) .70 0.15 (0.30) .01
RCF
No. 24 23 20
RCF 0.85 (1.23) 0.64 (1.20) .60 0.17 (0.34) .048
RCF, excluding cephalic arch and
central vein procedures
0.85 (1.23) 0.64 (1.20) .60 0.17 (0.34) .048
BCF
No. 27 27 28
BCF 0.60 (1.00) 0.83 (1.6) .69 0.27 (0.57) .29
BCF, excluding cephalic arch and
central vein procedures
0.58 (0.98) 0.74 (1.66) 1.00 0.13 (0.28) .06
AVF, Arteriovenous ﬁstula; BCF, brachiocephalic ﬁstula; RCF, radiocephalic ﬁstula.
Values are reported as mean (standard deviation).
aProcedure days rate to restore or to maintain patency per year at risk deﬁned as the total number of procedure days to restore or to maintain
patency/time on trial.
bExcludes one subject in the 10-mg group and one subject in the 30-mg group who discontinued on day 1 without any procedure data.
cP values vs placebo from a Wilcoxon rank sum test.
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reduction was even greater when balloon angioplasty
procedures directed at cephalic arch and central vein
stenosis were excluded. The vonapanitase treatment ef-
fect was greater in those with radiocephalic AVFs than
in those with brachiocephalic AVFs. Radiocephalic AVFs
typically fail because of stenosis, occurring predomi-
nantly in the perianastomotic area, an area within the
treatment zone of vonapanitase, which may explain the
superior efﬁcacy of vonapanitase in this AVF type.12,13
Vonapanitase fragments elastin in the vessel adventitia,
liberating peptide fragments. Studies with a porcine
homologue of vonapanitase have shown that elastin
fragments are chemoattractants for cells that participate
in the formation of intimal hyperplasia.6-8 Peptide
fragments created in the adventitia may retain scar-
forming cells in the adventitia, thereby decreasing
migration to the lumen and lumen stenosis after vessel
injury.14,15 In a previous publication of data from this trial,
duplex Doppler ultrasound examinations showed less
hemodynamically signiﬁcant stenosis in vonapanitase-
treated AVFs.10 In the radiocephalic AVFs at week 6,
hemodynamically signiﬁcant stenosis in the treatment
zone was present in 55% of placebo patients and 26%
of vonapanitase patients (P ¼ .02). Vonapanitase treat-
ment can also cause arterial and venous dilation through
lysis of elastic ﬁbers that normally constrain vessel
diameter.16,17 Finally, in experimental models in animals,
fragmentation of elastin is an early and essential compo-
nent of vascular remodeling that is necessary for AVF
maturation.18 Application of vonapanitase, an elastase,
to the AVF immediately after creation could accelerate
vascular remodeling that could promote AVF matura-
tion. The previously published data showed that vonapa-
nitase signiﬁcantly increased the proportion of patients
with a mature AVF by ultrasound criteria within 6 to
12 weeks.10
Ultrasound-deﬁned maturation in a good predictor of
successful AVF use for hemodialysis.19 Approximately
70% of the patients were on hemodialysis at some
time during the study. In this subgroup, approximately
half had unassisted use of the AVF for hemodialysis,
and an additional 20% had assisted use of the AVF for
hemodialysis. AVF use for hemodialysis was deﬁned as
use of the trial AVF for hemodialysis for $3 months. If
hemodialysis was not initiated at least 3 months before
the last visit, successful use was deﬁned as use for at least
1 month and in use at the patient’s last study visit. This
deﬁnition was chosen because the majority of investiga-
tors were surgeons who did not have access to dialysis
blood ﬂow data. This deﬁnition is practical as this dura-
tion of use is signiﬁcant and a poorly functioning AVF
would not be tolerated over such a time frame. There
were no signiﬁcant differences between treatment
groups for either successful unassisted or any use for
hemodialysis. In the subset with radiocephalic AVF, there
was a trend for more successful use of the ﬁstula in the
30-mg group. This was also the group in which vonapani-
tase was associated with the greatest increase in AVF
maturation.10
CONCLUSIONS
In this study, vonapanitase did not signiﬁcantly improve
primary patency in the overall analysis but did signiﬁ-
cantly improve primary patency for vonapanitase overall
and 30 mg in an analysis that excluded patency loss due
to cephalic arch and central vein balloon angioplasty. In
radiocephalic patients, vonapanitase overall and 30 mg
signiﬁcantly improved primary and secondary patency
and reduced the rate of procedures to restore or to main-
tain patency. Phase 3 conﬁrmatory trials (NCT02110901
and NCT02414841) are under way in patients undergoing
creation of radiocephalic AVFs.
Pamela Gustafson, Francesca Lindow, Missy Magill,
Holly Knight, Marco Wong, and Michelle Currie contrib-
uted to trial design, protocol development, trial opera-
tions, data analysis, and report writing. The work of
many investigators and trial coordinators made this trial
possible. The principal investigators, sites, and numbers
treated by site were as follows: R. J. Hye, Kaiser Perma-
nente San Diego, San Diego, Calif, 25; E. K. Peden, The
Methodist Hospital, Houston, Tex, 18; A. D. Sam, Vascular
Specialty Center, Baton Rouge, La, 15; T. P. O’Connor,
Renal Care Associates, Peoria, Ill, 14; B. J. Browne,
California Institute of Renal Research, San Diego, Calif,







All AVFs n ¼ 51 n ¼ 51 n ¼ 49
Unassisted
usedyes
20 (50) 19 (51) 24 (60)
Any usebdyes 28 (70) 25 (68) 30 (75)
Indeterminatec 11 14 9
RCF n ¼ 24 n ¼ 23 n ¼ 20
Unassisted
usedyes
5 (28) 5 (29) 8 (53)
Any usebdyes 10 (56) 12 (68) 12 (80)
Indeterminatec 6 6 5
BCF n ¼ 27 n ¼ 28 n ¼ 29
Unassisted
usedyes
12 (55) 12 (60) 16 (64)
Any usebdyes 18 (82) 13 (65) 18 (72)
Indeterminatec 5 8 4
BCF, Brachiocephalic ﬁstula; RCF, radiocephalic ﬁstula.
Values are reported as No. (%).
aExcludes patients with indeterminate use (ie, those with a patent AVF
who never initiated hemodialysis) from the denominator for percent-
age calculation.
bAny use includes unassisted and assisted use (meaning procedures to
restore or to maintain patency of the AVF before use).
cUse or nonuse could not be determined because of not being on
hemodialysis and not having had the AVF abandoned.
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11; A. S. Schanzer, University of Massachusetts, Worcester,
Mass, 11; S. C. Jensik, Rush University Medical Center, Chi-
cago, Ill, 11; B. S. Dixon, University of Iowa, Iowa City, Iowa,
6; M. J. Moritz, Lehigh Valley Hospital, Allentown, Pa, 6;
A. M. Duda, Sparrow Clinical Research Institute, Lans-
ing, Mich, 6; A. J. Dwivedi, University of Louisville, Louis-
ville, Ky, 6; C. M. Eichler and M. S. Conte, University
of California, San Francisco, San Francisco, Calif, 5;
D. Lorelli, Renaissance Renal Research Institute, Detroit,
Mich, 2; J. H. Lawson, Duke Medical Center, Durham, NC,
2; E. S. Schuman, Legacy Oregon Surgical, Portland,
Ore, 2; V. A. Scavo, Indiana/Ohio Heart, Fort Wayne,
Ind, 2; A. G. Akingba, Indiana University, Indianapolis,
Ind, 2; M. H. Glickman, Vascular & Transplant Specialists,
Norfolk, Va, 2; S. R. Johnson, Beth Israel Deaconess Hos-
pital, Boston, Mass, 1; D. Schaffer, Vanderbilt University,
Nashville, Tenn, 1; L. A. Scher, Monteﬁore Medical Cen-
ter, Bronx, NY, 1; D. B. Leeser and S. Kapur, Weill Cornell
Medical College, New York, NY, 1; M. T. Menard, Brigham
& Women’s Hospital, Boston, Mass, 1.
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